Influenza virus vaccine trivalent - GC Pharma

Drug Profile

Influenza virus vaccine trivalent - GC Pharma

Alternative Names: GC 501; GC FLU; GCFlu®; Inactivated, split virion, influenza virus vaccine - GC Pharma; Seasonal influenza virus vaccine - GC Pharma; Trivalent influenza virus vaccine - GC Pharma

Latest Information Update: 07 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 15 Mar 2011 Influenza virus vaccine trivalent (GC FLU®) receives WHO prequalification status for Influenza virus infections (prevention)
  • 01 Jan 2010 Launched for Influenza virus infections in South Korea (IM)
  • 01 Sep 2008 Phase-III clinical trials in Influenza virus infections in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top